128 related articles for article (PubMed ID: 35005654)
1. A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC.
Camidge DR; Barlesi F; Goldman JW; Morgensztern D; Heist R; Vokes E; Angevin E; Hong DS; Rybkin II; Barve M; Bauer TM; Delmonte A; Dunbar M; Motwani M; Parikh A; Noon E; Wu J; Blot V; Kelly K
JTO Clin Res Rep; 2022 Jan; 3(1):100262. PubMed ID: 35005654
[TBL] [Abstract][Full Text] [Related]
2. Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma.
Camidge DR; Morgensztern D; Heist RS; Barve M; Vokes E; Goldman JW; Hong DS; Bauer TM; Strickler JH; Angevin E; Motwani M; Parikh A; Sun Z; Bach BA; Wu J; Komarnitsky PB; Kelly K
Clin Cancer Res; 2021 Nov; 27(21):5781-5792. PubMed ID: 34426443
[TBL] [Abstract][Full Text] [Related]
3. Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.
Camidge DR; Barlesi F; Goldman JW; Morgensztern D; Heist R; Vokes E; Spira A; Angevin E; Su WC; Hong DS; Strickler JH; Motwani M; Dunbar M; Parikh A; Noon E; Blot V; Wu J; Kelly K
J Clin Oncol; 2023 Feb; 41(5):1105-1115. PubMed ID: 36288547
[TBL] [Abstract][Full Text] [Related]
4. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
Strickler JH; Weekes CD; Nemunaitis J; Ramanathan RK; Heist RS; Morgensztern D; Angevin E; Bauer TM; Yue H; Motwani M; Parikh A; Reilly EB; Afar D; Naumovski L; Kelly K
J Clin Oncol; 2018 Nov; 36(33):3298-3306. PubMed ID: 30285518
[TBL] [Abstract][Full Text] [Related]
5. Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Non-Squamous EGFR-Wildtype NSCLC in the Phase 2 LUMINOSITY Trial.
Camidge DR; Bar J; Horinouchi H; Goldman J; Moiseenko F; Filippova E; Cicin I; Ciuleanu T; Daaboul N; Liu C; Bradbury P; Moskovitz M; Katgi N; Tomasini P; Zer A; Girard N; Cuppens K; Han JY; Wu SY; Baijal S; Mansfield AS; Kuo CH; Nishino K; Lee SH; Planchard D; Baik C; Li M; Ansell P; Xia S; Bolotin E; Looman J; Ratajczak C; Lu S
J Clin Oncol; 2024 Jun; ():JCO2400720. PubMed ID: 38843488
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors.
Fujiwara Y; Kenmotsu H; Yamamoto N; Shimizu T; Yonemori K; Ocampo C; Parikh A; Okubo S; Fukasawa K; Murakami H
Cancer Med; 2021 Apr; 10(7):2350-2358. PubMed ID: 33675179
[TBL] [Abstract][Full Text] [Related]
7. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer
Niu J; Maurice-Dror C; Lee DH; Kim DW; Nagrial A; Voskoboynik M; Chung HC; Mileham K; Vaishampayan U; Rasco D; Golan T; Bauer TM; Jimeno A; Chung V; Chartash E; Lala M; Chen Q; Healy JA; Ahn MJ
Ann Oncol; 2022 Feb; 33(2):169-180. PubMed ID: 34800678
[TBL] [Abstract][Full Text] [Related]
8. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
Wrangle JM; Velcheti V; Patel MR; Garrett-Mayer E; Hill EG; Ravenel JG; Miller JS; Farhad M; Anderton K; Lindsey K; Taffaro-Neskey M; Sherman C; Suriano S; Swiderska-Syn M; Sion A; Harris J; Edwards AR; Rytlewski JA; Sanders CM; Yusko EC; Robinson MD; Krieg C; Redmond WL; Egan JO; Rhode PR; Jeng EK; Rock AD; Wong HC; Rubinstein MP
Lancet Oncol; 2018 May; 19(5):694-704. PubMed ID: 29628312
[TBL] [Abstract][Full Text] [Related]
9. First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients.
O'Byrne KJ; Lee KH; Kim SW; Park K; Nishio M; Sakai H; Ohe Y; Fukuhara T; Kang JH; Daga H; Yu CJ; Hotta K; Tanaka H; Takeda M; Yokoyama T; Nathan FE; Lee JS
ESMO Open; 2022 Feb; 7(1):100394. PubMed ID: 35158207
[TBL] [Abstract][Full Text] [Related]
10. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.
Yu EY; Petrylak DP; O'Donnell PH; Lee JL; van der Heijden MS; Loriot Y; Stein MN; Necchi A; Kojima T; Harrison MR; Hoon Park S; Quinn DI; Heath EI; Rosenberg JE; Steinberg J; Liang SY; Trowbridge J; Campbell M; McGregor B; Balar AV
Lancet Oncol; 2021 Jun; 22(6):872-882. PubMed ID: 33991512
[TBL] [Abstract][Full Text] [Related]
11. Ceritinib plus Nivolumab in Patients with Advanced ALK-Rearranged Non-Small Cell Lung Cancer: Results of an Open-Label, Multicenter, Phase 1B Study.
Felip E; de Braud FG; Maur M; Loong HH; Shaw AT; Vansteenkiste JF; John T; Liu G; Lolkema MP; Selvaggi G; Giannone V; Cazorla P; Baum J; Balbin OA; Wang LV; Lau YY; Scott JW; Tan DS
J Thorac Oncol; 2020 Mar; 15(3):392-403. PubMed ID: 31634667
[TBL] [Abstract][Full Text] [Related]
12. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
Antonia S; Goldberg SB; Balmanoukian A; Chaft JE; Sanborn RE; Gupta A; Narwal R; Steele K; Gu Y; Karakunnel JJ; Rizvi NA
Lancet Oncol; 2016 Mar; 17(3):299-308. PubMed ID: 26858122
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Hellmann MD; Paz-Ares L; Bernabe Caro R; Zurawski B; Kim SW; Carcereny Costa E; Park K; Alexandru A; Lupinacci L; de la Mora Jimenez E; Sakai H; Albert I; Vergnenegre A; Peters S; Syrigos K; Barlesi F; Reck M; Borghaei H; Brahmer JR; O'Byrne KJ; Geese WJ; Bhagavatheeswaran P; Rabindran SK; Kasinathan RS; Nathan FE; Ramalingam SS
N Engl J Med; 2019 Nov; 381(21):2020-2031. PubMed ID: 31562796
[TBL] [Abstract][Full Text] [Related]
14. Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non-Small Cell Lung Cancer: A Phase 1 Trial.
Wang Z; Ying J; Xu J; Yuan P; Duan J; Bai H; Guo C; Li L; Yang Z; Wan R; Fei K; Zhao Z; Du X; Zhao J; Lv N; Wang J
JAMA Netw Open; 2020 Oct; 3(10):e2013770. PubMed ID: 33017026
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung Cancer.
Inoue Y; Yoshimura K; Nishimoto K; Inui N; Karayama M; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Asada K; Uto T; Fujii M; Matsui T; Matsuura S; Hashimoto D; Toyoshima M; Kusagaya H; Matsuda H; Inami N; Kaida Y; Niwa M; Ito Y; Sugimura H; Suda T
JAMA Netw Open; 2020 Sep; 3(9):e2011818. PubMed ID: 32955570
[TBL] [Abstract][Full Text] [Related]
16. Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China.
Teng MM; Chen SY; Yang B; Wang Y; Han RY; An MN; Dong YL; You HS
Cancer Med; 2021 Sep; 10(18):6344-6353. PubMed ID: 34382361
[TBL] [Abstract][Full Text] [Related]
17. Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study.
Zucali PA; Lin CC; Carthon BC; Bauer TM; Tucci M; Italiano A; Iacovelli R; Su WC; Massard C; Saleh M; Daniele G; Greystoke A; Gutierrez M; Pant S; Shen YC; Perrino M; Meng R; Abbadessa G; Lee H; Dong Y; Chiron M; Wang R; Loumagne L; Lépine L; de Bono J
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35058326
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer: a meta-analysis of prospective clinical trials.
Huang J; Zhang Y; Sheng J; Zhang H; Fang W; Zhan J; Zhou T; Chen Y; Liu L; Zhang L
Onco Targets Ther; 2016; 9():5867-5874. PubMed ID: 27713640
[TBL] [Abstract][Full Text] [Related]
19. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
